14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta.

Mutations in alpha-synuclein have been identified in some rare families with autosomal dominant Parkinson's disease (PD). The synuclein gene family shares physical and functional homology with 14-3-3 proteins and binds to 14-3-3 proteins and to its ligands. We therefore investigated whether 14-3-3 proteins are also involved in the pathogenesis of PD. Here we demonstrate that 14-3-3 proteins are colocalized with Lewy bodies in PD. We investigated the 14-3-3 eta (YWHAH) gene by mutation analysis and association studies as it maps to human chromosome 22q12.1-q13.1, a region which has been recently implicated in PD and carried out immunohistochemical studies of Lewy bodies with two different 14-3-3 eta antibodies. In 358 sporadic and familial PD patients, disease causing mutations were not identified. Furthermore, association studies with intragenic polymorphisms do not provide evidence for an involvement of 14-3-3 eta in the pathogenesis of PD. In accordance with these findings, there was no staining of substantia nigra Lewy bodies with antibodies specific for the 14-3-3 eta subunit.

[1]  S. Leal,et al.  Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? , 1997, Annals of neurology.

[2]  J. Idle,et al.  Mutant debrisoquine hydroxylation genes in Parkinson's disease , 1992, The Lancet.

[3]  A. Svejgaard,et al.  HLA and disease associations: detecting the strongest association. , 1994, Tissue antigens.

[4]  E J Louis,et al.  An exact test for Hardy-Weinberg and multiple alleles. , 1987, Biometrics.

[5]  U. Keil,et al.  A Single Question about Prior Stroke versus a Stroke Questionnaire to Assess Stroke Prevalence in Populations , 2000, Neuroepidemiology.

[6]  A. Aitken.  14-3-3 and its possible role in co-ordinating multiple signalling pathways. , 1996, Trends in cell biology.

[7]  J. Lowe,et al.  Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins , 1996, Neuroscience Letters.

[8]  K. Irie,et al.  14-3-3 proteins: potential roles in vesicular transport and Ras signaling in Saccharomyces cerevisiae. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Jackson,et al.  Purification, Properties, and Immunohistochemical Localisation of Human Brain 14‐3‐3 Protein , 1982, Journal of neurochemistry.

[10]  T. Arinami,et al.  Systematic search for mutations in the 14-3-3 eta chain gene on chromosome 22 in schizophrenics. , 1998, Psychiatric genetics.

[11]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  F. Rousset,et al.  Testing heterozygote excess and deficiency. , 1995, Genetics.

[13]  J. Schulz,et al.  Parkinson's disease: one biochemical pathway to fit all genes? , 2002, Trends in molecular medicine.

[14]  Anthony J. Muslin,et al.  14‐3‐3 proteins block apoptosis and differentially regulate MAPK cascades , 2000, The EMBO journal.

[15]  A. Svejgaard,et al.  HLA and Disease 1982 ‐ A Survey , 1983, Immunological reviews.

[16]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[17]  N. Shimizu,et al.  Structural organization and chromosomal assignment of the human 14-3-3 eta chain gene (YWHAH). , 1996, Genomics.

[18]  M. Waye,et al.  Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase , 2000, Oncogene.

[19]  V. Dixit,et al.  14-3-3 Proteins Associate with A20 in an Isoform-specific Manner and Function Both as Chaperone and Adapter Molecules* , 1996, The Journal of Biological Chemistry.

[20]  H. Betz,et al.  Dominant‐negative alleles of 14‐3‐3 proteins cause defects in actin organization and vesicle targeting in the yeast Saccharomyces cerevisiae , 1999, FEBS letters.

[21]  T. Isobe,et al.  Brain 14‐3‐3 protein is an activator protein that activates tryptophan 5‐monooxygenase and tyrosine 3‐monooxygenase in the presence of Ca2+,calmodulin‐dependent protein kinase II , 1987, FEBS letters.

[22]  Y. Agid,et al.  14‐3‐3 Protein cerebrospinal fluid detection in human growth hormone–treated Creutzfeldt‐Jakob disease patients , 2001, Annals of neurology.

[23]  H. Fu,et al.  Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Tolosa,et al.  Detection of 14‐3‐3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders , 1999, Annals of neurology.

[25]  M. Pangalos,et al.  Association of GABAB Receptors and Members of the 14-3-3 Family of Signaling Proteins , 2001, Molecular and Cellular Neuroscience.

[26]  M. Kimura,et al.  14-3-3 Is Involved in p75 Neurotrophin Receptor-mediated Signal Transduction* , 2001, The Journal of Biological Chemistry.

[27]  N. Shimizu,et al.  cDNA cloning and chromosome assignment of the gene for human brain 14–3–3 protein η chain , 1992, Journal of neuroscience research.

[28]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[29]  J. Kornhuber,et al.  Isoform Pattern of 14‐3‐3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt‐Jakob Disease , 1999, Journal of neurochemistry.

[30]  Masahiko Watanabe,et al.  Molecular cloning of cDNA to rat 14-3-3 η chain polypeptide and the neuronal expression of the mRNA in the central nervous system , 1991 .

[31]  Masahiko Watanabe,et al.  Molecular cloning of rat cDNAs for the ζ and θ subtypes of 14-3-3 protein and differential distributions of their mRNAs in the brain , 1994 .

[32]  O. Gefeller,et al.  Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease , 1998, Annals of neurology.

[33]  François Rousset,et al.  GENEPOP (version 1.2): population genetic software for exact tests and ecumenicism , 1995 .

[34]  D. Collier,et al.  Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in schizophrenia. , 2000, American journal of medical genetics.

[35]  H. Leffers,et al.  Assignment of the human genes encoding 14,3-3 Eta (YWHAH) to 22q12, 14-3-3 zeta (YWHAZ) to 2p25.1-p25.2, and 14-3-3 beta (YWHAB) to 20q13.1 by in situ hybridization. , 1996, Genomics.

[36]  H. Budka,et al.  14‐3‐3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains , 2002, Journal of neuropathology and experimental neurology.

[37]  M. Polymeropoulos,et al.  Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.

[38]  J. Rostas,et al.  Subcellular Localisation of 14‐3‐3 Isoforms in Rat Brain Using Specific Antibodies , 1994, Journal of neurochemistry.

[39]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[40]  R. Kuwano,et al.  Widespread Distribution of the 14‐3‐3 Protein in Vertebrate Brains and Bovine Tissues: Correlation with the Distributions of Calcium‐Dependent Protein Kinases , 1991, Journal of neurochemistry.

[41]  P. Boston,et al.  Human 14‐3‐3 Protein: Radioimmunoassay, Tissue Distribution, and Cerebrospinal Fluid Levels in Patients with Neurological Disorders , 1982, Journal of neurochemistry.

[42]  S. Howell,et al.  14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF. , 1995, The Journal of biological chemistry.